Medicines Update: May 2026

This medicines update is provided by the Veterinary Medicines Directorate (VMD) and lists new active substance, new marketing authorisations and changes to authorisations most relevant to vets.

New marketing authorisations

Novel products

Lenivia Solution for Injection for Dogs (Range 0.5 mg – 3.0 mg) is the first authorised veterinary medicine containing the active substance izenivetmab. The product is indicated for the alleviation of pain associated with osteoarthritis (OA) in dogs. The recommended dose is 0.05-0.1 mg/kg body weight, once every three months.

Table 1 shows the new marketing authorisations for May 2026

TABLE 1: New marketing authorisations in May 2026

New Marketing Authorisations			
Product name and target species	**Active substance**	**Authorisation Holder, territory, and distribution category**	**Therapeutic group**
Food Animals			
Flortekxin 300 mg/ml + 16.5 mg/ml Solution for Injection for Cattle	Florfenicol, Flunixin	Laboratorios Karizoo S.A GB, POM-V	Antimicrobial; Anti Inflammatory
Quinox 6 mg/g Oral Powder for Cattle and Sheep	Decoquinate	Huvepharma NV NI, POM-V	Antiprotozoal anticoccidial
Quinox 60.6 mg/g Premix for Medicated Feeding Stuff for Cattle and Sheep	Decoquinate	Huvepharma NV NI, POM-V	Antiprotozoal anticoccidial
Lenivia 0.5 mg Solution for Injection for Dogs Lenivia 1 mg Solution for Injection for Dogs Lenivia 1.5 mg Solution for Injection for Dogs Lenivia 2 mg Solution for Injection for Dogs Lenivia 3 mg Solution for Injection for Dogs	Izenivetmab	Zoetis UK Limited GB, POM-V	Other analgesics and antipyretics

See the VMD's Product Information Database (www.gov.uk/check-animal-medicine-licensed) for more information on each of these products. There may be a delay before formal documentation is available for some Northern Ireland products, from the European Medicines Agency.
The timing of the product being placed on the market is an issue for the marketing authorisation holder.

Changes to authorisations most relevant to vets
The changes to authorisations most relevant to vets can be found below. Each product is listed, along with the authorisation holder, distribution category and details of which Summary of Product Characteristics (SPC) sections have been revised/changed.

Changes to the SPC, labels and leaflets may change how the medicines should be used. Details can be found on the VMD's Product Information Database (PID) at www.gov.uk/check-animal-medicine-licensed.

Due to ongoing assessments, there may be a delay between the point at which a new change is authorised and the updated SPC being available on the PID. There may also be a delay between the point at which any SPC changes are authorised and implementation in the product literature. Unless you have been advised otherwise, the labelling instructions on the pack which is dispensed should be followed.

Food producing animals

Avishield IB GI-13, Lyophilisate for Oculonasal Suspension/Use in Drinking Water for Chickens
Avishield IB H120, Lyophilisate for Oculonasal Suspension/Use in Drinking Water for Chickens
Genera d.d. NI POM-V

Section 3.8 of the SPC: Added the claim for mixed use of three (Avishield IB GI-13, Avishield IB H120, and Avishield IB QX) or two (Avishield IB GI-13and Avishield IB H120) vaccines for administration to chickens via spray method.

Combiclav Suspension for Injection (Cattle)
Norbrook Laboratories Limited UK POM-V

Section 4.6 of the SPC: Allergic reactions (allergic skin reactions, anaphylaxis) may occasionally occur. If allergic reactions occur, the product should be discontinued immediately. Appropriate symptomatic treatment should be initiated.

Depocillin 300 mg/ml suspension for injection (cattle, horses, sheep, pigs, dogs, cats)
Intervet International B.V. UK POM-V

Section 3.9 of the SPC: The appropriate treatment duration should be chosen based on the clinical needs and individual recovery of the treated animal. Consideration should be given to the accessibility of the target tissue and characteristics of the target pathogen.

Prasequine 1 mg Tablets for Horses
CP Pharma Handelsgesellschaft mbH GB & NI POM-V

Section 3.5 (NI)/4.5 (GB) of the SPC updated user safety precautions: Pergolide, like other ergot derivatives, may cause emesis, dizziness, lethargy or low blood pressure. Severe adverse events such as collapse have been observed. Ingestion may be harmful and associated with severe adverse events, especially in children or people with pre-existing heart conditions. Do not ingest this veterinary medicinal product.

Section 3.6 (NI)/4.6 (GB) updated adverse events:
'Rare' frequency, i.e. 1 to 10 animals/10,000 treated: inappetence, transient anorexia and lethargy, central nervous system disorder (e.g., mild central nervous system depression and mild ataxia), diarrhoea, colic.
'Very rare' frequency, i.e. <1 animal / 10 000 animals treated, including isolated reports: Increased sweating.

Startvac Emulsion for Injection for Cattle
Laboratorios Hipra SA NI POM-V

Section 3.9 of the SPC: To allow the current vaccination schedule to be administered independently of the parturition date, with booster doses given every three months.

Companion animals

Frontpro Chewable Tablets for Dogs (Range)
Boehringer Ingelheim Vetmedica Gmbh GB NFA-VPS

Section 3.2 of the SPC: Addition of indication for the treatment of tick infestation in dogs caused by *Ixodes hexagonus*. One treatment provides immediate and persistent tick killing activity for one month.

Librela Solution for Injection for Dogs (Range)
Zoetis UK Limited GB POM-V

Section 4.5 of SPC: Addition of the following special precaution for use in animals: Where a dog presents with new or increased joint swelling and/or joint pain following Librela treatment (see section 4.6), consideration should be given to perform additional diagnostics and discontinue treatment on a case-by-case basis.

Section 4.6: Addition of the following adverse events, all with 'very rare' frequency, i.e. <1 animal / 10,000 animals treated, including isolated reports: joint swelling, joint pain, bone and joint disorder, soft tissue ossification.
The following accompanying note has been added: 'New bone formation, coupled with joint swelling and/or pain, affecting the periosteum, joint capsule and adjacent soft tissues has been observed following repeated administration. Radiographically or on cross sectional imaging this is defined by extensive, irregular periosteal and ectopic mineralized tissue formation that extends beyond normal chondro-osseous margins into the metaphyseal and, in some cases, diaphyseal regions of adjacent bones. Bone alterations, including focal osteolysis or erosions may be observed. These changes may present unilaterally or bilaterally, can affect multiple joints, may be progressive and in very rare cases have been associated with fracture.'

Bravecto 150 mg/ml powder and solvent for suspension for injection for dogs
MSD Animal Health UK Limited GB POM-V

Section 4.6 of the SPC: Emesis and diarrhoea can occur rarely (1 to 10 animals / 10,000 animals treated) following administration of the veterinary medicinal product. Allergic oedema, hypersensitivity reaction and pruritus can occur very rarely (<1 animal / 10,000 animals treated, including isolated reports) following administration of the veterinary medicinal product.

Section 4.5 update of special precautions to be taken by the person administering the product to animals: If accidental skin exposure occurs, wash the skin immediately with soap and water. If accidental eye exposure occurs, flush eyes immediately with clean water.

For more information, contact the VMD at postmaster@vmd.gov.uk